Drug Profile
Lamivudine/stavudine - Viatris
Alternative Names: Stavudine/lamivudine - Matrix laboratoriesLatest Information Update: 18 Dec 2020
Price :
$50
*
At a glance
- Originator Matrix Pharmaceutical; Mylan
- Developer Matrix Pharmaceutical
- Class Antiretrovirals; Deoxyribonucleosides; Dideoxynucleosides; Nucleosides; Pyrimidine nucleosides; Small molecules
- Mechanism of Action Nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered HIV-1 infections
Most Recent Events
- 21 Nov 2018 Lamivudine/stavudine is not yet avaliable in USA for HIV-1 infections (Mylan Laboratories website, November 2018)